Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

Abstract Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A rec...

Full description

Bibliographic Details
Main Authors: Yu Chen, Ping Chi
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Journal of Hematology & Oncology
Online Access:http://link.springer.com/article/10.1186/s13045-018-0622-4
id doaj-ad5d70f5027a4029a58b49c352f00170
record_format Article
spelling doaj-ad5d70f5027a4029a58b49c352f001702020-11-24T20:40:21ZengBMCJournal of Hematology & Oncology1756-87222018-06-011111510.1186/s13045-018-0622-4Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancersYu Chen0Ping Chi1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterAbstract Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent “basket” study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing “tumor-agnostic” targeted therapies in rare tumors.http://link.springer.com/article/10.1186/s13045-018-0622-4
collection DOAJ
language English
format Article
sources DOAJ
author Yu Chen
Ping Chi
spellingShingle Yu Chen
Ping Chi
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Journal of Hematology & Oncology
author_facet Yu Chen
Ping Chi
author_sort Yu Chen
title Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_short Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_full Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_fullStr Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_full_unstemmed Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_sort basket trial of trk inhibitors demonstrates efficacy in trk fusion-positive cancers
publisher BMC
series Journal of Hematology & Oncology
issn 1756-8722
publishDate 2018-06-01
description Abstract Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent “basket” study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing “tumor-agnostic” targeted therapies in rare tumors.
url http://link.springer.com/article/10.1186/s13045-018-0622-4
work_keys_str_mv AT yuchen baskettrialoftrkinhibitorsdemonstratesefficacyintrkfusionpositivecancers
AT pingchi baskettrialoftrkinhibitorsdemonstratesefficacyintrkfusionpositivecancers
_version_ 1716827221662892032